Brain Tumor Pathology

Papers
(The TQCC of Brain Tumor Pathology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
H3 G34-mutant high-grade glioma32
Glioblastomas harboring gene fusions detected by next-generation sequencing26
Central nervous system neuroepithelial tumors with MN1-alteration: an individual patient data meta-analysis of 73 cases23
The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles21
The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system19
EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations17
Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L115
Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas14
Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort14
Prognostic significance of brain invasion in meningiomas: systematic review and meta-analysis14
Primary spinal intramedullary Ewing-like sarcoma harboring CIC-DUX4 translocation: a similar cytological appearance as its soft tissue counterpart but no lobulation in association with desmoplastic st13
Molecular subtyping of ependymoma and prognostic impact of Ki-6712
Placental alkaline phosphatase in cerebrospinal fluid as a biomarker for optimizing surgical treatment strategies for pineal region germ cell tumors11
Ependymoma with C11orf95-MAML2 fusion: presenting with granular cell and ganglion cell features11
The proteomic analysis shows enrichment of RNA surveillance pathways in adult SHH and extensive metabolic reprogramming in Group 3 medulloblastomas11
Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma10
Diffuse midline glioma of the cervical spinal cord with H3 K27M genotype phenotypically mimicking anaplastic ganglioglioma: a case report and review of the literature10
Spinal cord astroblastoma with EWSR1-BEND2 fusion classified as HGNET-MN1 by methylation classification: a case report10
Implications of immune cells in oncolytic herpes simplex virotherapy for glioma9
Epithelioid inflammatory myofibroblastic sarcoma with VCL–ALK fusion of central nervous system: case report and brief review of the literature8
Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options8
Intracranial angiomatoid fibrous histiocytoma with rhabdoid features: a mimic of rhabdoid meningioma8
Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features8
Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors8
Central nervous system neuroblastic tumor with FOXR2 activation presenting both neuronal and glial differentiation: a case report8
Central nervous system high grade neuroepithelial tumor with BCOR immunopositivity: Is there a molecular heterogeneity?7
Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas7
Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy7
Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR7
Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas6
Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development6
Liquid biomarkers in glioma6
Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas6
0.01697301864624